Marvin Gatz
Pulmonary Disease · Fair Oaks, CANPI 1982627824
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations.
Across 155 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$585
- Boehringer Ingelheim$358
- Genentech USA, Inc.$205
- AbbVie$204
- AstraZeneca$152
- Mylan Specialty L.p.$130
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,62297%
- Education$753%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 35 | $585 |
| Boehringer Ingelheim | 17 | $358 |
| Genentech USA, Inc. | 4 | $205 |
| AbbVie | 14 | $204 |
| AstraZeneca(2 entities) | 8 | $152 |
| Mylan Specialty L.p. | 8 | $130 |
| Sunovion Pharmaceuticals Inc. | 13 | $103 |
| Grifols USA, LLC | 5 | $102 |
| Electromed, Inc. | 12 | $100 |
| Shire North American Group Inc | 4 | $89 |
| Insmed, Inc. | 1 | $75 |
| Merck | 5 | $72 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $60 |
| Optinose US, Inc. | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Kaleo, Inc. | 2 | $43 |
| Bayer | 2 | $41 |
| Advanced Respiratory, Inc | 3 | $36 |
| Paratek Pharmaceuticals, Inc. | 2 | $35 |
| Philips North America LLC | 2 | $35 |
| Circassia Inc. | 2 | $32 |
| Harmony Biosciences LLC | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| United Therapeutics Corporation | 1 | $19 |
| Vyera Pharmaceuticals, LLC | 1 | $19 |
| Covis Pharma GmbH | 1 | $19 |
| Pfizer | 1 | $18 |
| Gilead | 1 | $14 |
| Fisher & Paykel Healthcare Inc | 1 | $11 |
How this compares
$2,697 in reported general payments places this provider in the 60th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Fair Oaks
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.